go-v.orgdoi

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil

Yukihisa Tamaki, Yoko Hieda, Masanobu Nakajima, Kazuhiro Kitajima, Rika Yoshida, Takeshi Yoshizako, Atsushi Ue, Mutsumi Tokudo, Noriyuki Hirahara, Ichiro Moriyama, Hiroyuki Kato, T Inomata · Journal of Cancer · 2018

  • DOI 10.7150/jca.23456
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2018

Abstract

Purpose: To compare treatment outcomes and adverse events between concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) and conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil (CF-RT).

Methods and Materials:We retrospectively investigated treatment outcomes and adverse events in 121 patients with advanced esophageal cancer who underwent concurrent chemoradiotherapy with CF-RT (n = 83) or DCF-RT (n = 38).In the CF-RT group, patients were administered cisplatin (70 mg/m 2 ) and 5-fluorouracil (700 mg/m 2 ) for 5 days; in the DCF-RT group, patients were administered docetaxel (50 mg/m 2 ), cisplatin (50 mg/m 2 ), and 5-fluorouracil (500 mg/m 2 ) for 5 days.The radiotherapy dose was 1.8-2 Gy per session, up to a total of 50-60 Gy.Results: The complete response (CR) rate was 37.8% in the CF-RT group and 52.6% in the DCF-RT group.Overall survival (OS) rates at 2 and 3 years were 45.0% and 37.5%, respectively, in the CF-RT group and 62.9% and 56.7%, respectively, in the DCF-RT group, with a significant intergroup difference (p = 0.032).Progression-free survival rates at 2 and 3 years were 44.1% and 36.9%,respectively, in the CF-RT group and 45.0% and 45.0%, respectively, in the DCF-RT group (p = 0.10).Local control rates at 2 and 3 years were 59.1% and 54.6%, respectively, in the CF-RT group and 71.8% and 71.8%, respectively, in the DCF-RT group (p = 0.12).The incidence of Grade 3/4 leukopenia was 55.4% (n = 46) in the CF-RT group and 78.9% (n = 30) in the DCF-RT group, with a significant intergroup difference (p = 0.022).The incidence of Grade 3/4 neutropenia was 47.0% (n = 39) in the CF-RT group and 65.8% (n = 25) in the DCF-RT group, with a notable albeit not statistically significant difference between the groups (p = 0.054).There were no significant intergroup differences in anemia, thrombocytopenia, radiation-induced dermatitis, radiation esophagitis, or late adverse events.Conclusions: Rates of OS and CR were improved after treatment with DCF-RT compared with CF-RT.Although DCF-RT-treated patients had higher rates of leukopenia, treatment safety was Ivyspring International

Open the resolved locator · 10.7150/jca.23456

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:10 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v09p2765.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.